Signs of SIBO in Women: Symptoms, Causes and How It Damages Liver Function Over Time

You eat a healthy salad and spend the rest of the afternoon looking six months pregnant. You have cut out gluten, then dairy, then everything enjoyable — and your gut still behaves as though it has a personal vendetta against you. You are tired in a way sleep does not fix, your brain runs through fog, and your doctor keeps telling you the blood tests are "basically normal".

If that sounds familiar, there is a condition worth taking seriously that you may never have heard of, or heard of only in passing: small intestinal bacterial overgrowth (SIBO). And what is less well known still is that over time, untreated SIBO does not just wreck your digestion. It can quietly damage your liver.

SIBO symptoms at a glance

SIBO symptoms in women show up in two clusters: digestive and systemic. The most common include:

• Bloating and visible abdominal distension, often within 30 to 90 minutes of eating.

• Abdominal pain or cramping, and altered bowel habits (diarrhoea, constipation, or both).

• Excessive belching, flatulence, nausea and early fullness after small meals.

• Fatigue, brain fog and nutrient deficiencies (B12, iron, fat-soluble vitamins).

• Skin issues such as rosacea, plus histamine intolerance and mood changes.

What is SIBO?

Your gut houses trillions of bacteria, but they are not meant to be distributed evenly. The large intestine is supposed to be the bacterial metropolis. The small intestine, by contrast, is normally relatively sparse — fewer than 10³ colony-forming units per millilitre of fluid in the proximal small bowel.¹

SIBO occurs when bacteria — either relocated from the colon or overgrown from the small intestine's normal residents — proliferate there in numbers that disrupt normal digestive function. Prevalence estimates vary widely by diagnostic method, but studies suggest somewhere between 2.5–22% of the general population, with significantly higher rates among people with irritable bowel syndrome. One systematic review found SIBO prevalence in IBS patients ranging from roughly 4% to over 50% depending on the test used — culture-based methods giving the lowest estimates, breath tests the highest.²

Women are disproportionately represented in SIBO diagnoses. That is not coincidence: hormonal, anatomical and physiological factors specific to female biology all appear to influence gut motility and bacterial dynamics in meaningful ways.

Why women are more vulnerable

Hormones and gut motility

Sex hormones affect gastrointestinal function profoundly. Progesterone, which rises significantly during the luteal phase and in pregnancy, has well-documented inhibitory effects on gut motility, relaxing smooth muscle throughout the GI tract.³ Slower gut movement leaves food and bacteria in the small intestine longer — precisely the conditions that favour overgrowth.

This is why many women find their digestive symptoms worsen in the week before their period, or during pregnancy, when SIBO risk rises sharply. Pregnancy is associated with significantly slowed small bowel transit, particularly in the third trimester.⁴

Women with PCOS, who have chronically elevated androgens and altered sex hormone ratios, also show higher rates of gut dysbiosis and may be at elevated risk of altered gut microbial diversity.⁵ Women in perimenopause and menopause — where declining oestrogen accelerates changes in gut motility — likewise report increased GI symptoms that may partly reflect SIBO.

The hypothyroid connection

Hypothyroidism, which affects roughly five to ten times as many women as men, slows the whole body, gut included. Thyroid hormone is essential to maintaining the migrating motor complex (MMC) — the fasting "housekeeping" wave of contractions that sweeps bacteria out of the small intestine between meals.⁶ When thyroid function is suboptimal the MMC weakens and overgrowth becomes more likely. A study of hypothyroid patients found significantly higher SIBO prevalence than in euthyroid controls.⁷

Endometriosis

Endometriosis affects roughly 10% of women of reproductive age and, in a significant proportion of cases, produces lesions on and around the bowel. Those lesions can create adhesions, alter motility and disrupt the gut environment — all of which raise SIBO risk. In an uncontrolled case series of women with endometriosis and GI symptoms, 80% (40 of 50) showed bacterial overgrowth on breath testing, and more recent controlled studies confirm higher SIBO prevalence in endometriosis than in healthy women.⁸

Recognising SIBO: symptoms in women

SIBO wears many disguises, which is part of why it goes undiagnosed in women for years.

Digestive symptoms

• Bloating — the hallmark symptom. Often immediate, or appearing within 30–90 minutes of eating, and frequently severe ("I look pregnant"). It results from bacteria fermenting carbohydrates in the small intestine and producing excess gas.⁹

• Abdominal distension — visible expansion of the abdomen, particularly in the afternoon and evening.

• Abdominal pain or cramping, often relieved by defecation.

• Altered bowel habits — diarrhoea, constipation, or alternation between them, depending on the type of gas-producing bacteria involved:

  • Hydrogen-dominant SIBO is more commonly associated with diarrhoea.

  • Methane-dominant SIBO, now called intestinal methanogen overgrowth (IMO), is strongly associated with constipation — methane gas slows gut transit directly.¹⁰

  • Hydrogen sulphide SIBO is a newly recognised subtype, associated with diarrhoea and a distinctive sulphur odour.

• Excessive belching or flatulence.

• Nausea, particularly after eating.

• Feeling full quickly — early satiety.

Systemic symptoms

What makes SIBO genuinely systemic rather than merely a gut problem is its downstream effects:

• Fatigue and brain fog — bacterial overgrowth impairs absorption of key nutrients (vitamin B12, iron, fat-soluble vitamins) and produces toxins that circulate systemically.¹¹

• Nutrient deficiencies — malabsorption of B12 (consumed by the bacteria), of fat-soluble vitamins A, D, E and K when bile acids are deconjugated, and of iron are all well documented.¹²

• Joint pain — some research suggests bacterial products from SIBO may trigger systemic inflammation.

• Skin issues — rosacea has been significantly associated with SIBO across multiple studies. A 2008 study found that eradicating SIBO produced dramatic improvement or complete remission of rosacea in a majority of patients.¹³

• Restless legs syndrome — iron deficiency secondary to SIBO may be the driver.

• Anxiety and mood changes — the gut-brain axis runs both ways, and gut-derived metabolites from SIBO may influence neurotransmitter systems.¹⁴

• Histamine intolerance symptoms — certain SIBO-causing bacteria are high histamine producers; symptoms include flushing, hives, headaches and worsening allergy-like reactions.

What causes SIBO? The root triggers

Understanding cause is essential, because treating SIBO without addressing the underlying driver leads almost inevitably to recurrence.

1. Impaired migrating motor complex (MMC)

The MMC is the gut's self-cleaning cycle: a series of contractions sweeping the small intestine every 90–120 minutes during fasting, pushing bacteria downstream into the colon.¹⁵ It only activates in a fasted state, which is one reason constant grazing and snacking can predispose to SIBO. Anything that impairs the MMC — hypothyroidism, chronic stress, diabetes with autonomic neuropathy, proton pump inhibitor use — raises SIBO risk.⁶

2. Low stomach acid (hypochlorhydria)

Stomach acid is one of the body's primary defences against bacterial overgrowth, killing most bacteria before they can colonise the small intestine. Chronic PPI use — and tens of millions of people take them for acid reflux — significantly reduces stomach acid and has been associated with significantly increased SIBO risk.¹⁶ Ageing, autoimmune conditions affecting the stomach lining, and H. pylori infection also reduce acid secretion.

3. Structural abnormalities and post-surgical changes

Adhesions from previous abdominal surgery, diverticula in the small bowel, and strictures from conditions such as Crohn's disease all create anatomical pockets where bacteria pool and proliferate. Previous appendectomy and ileocecal valve dysfunction — the valve separating small and large intestine — are recognised risk factors too.¹⁷

4. Prior acute infections: post-infectious IBS and SIBO

A significant proportion of SIBO cases begin with acute gastroenteritis. Food poisoning and gut infections generate an immune response in which antibodies against the bacterial toxin CDT-B cross-react with vinculin, a protein critical to gut motility. That autoimmune process damages the enteric nervous system and impairs the MMC long after the acute infection has resolved.¹⁸ It is a major and historically underappreciated cause of chronic SIBO.

5. Stress and the gut-brain axis

Psychological stress profoundly alters gut motility, intestinal permeability and microbiome composition. Chronic stress activates the HPA axis, releasing cortisol and engaging the sympathetic nervous system — both of which suppress GI motility and alter the mucosal immune environment.¹⁹ Women with SIBO frequently have a history of chronic stress or significant adverse life events.

How SIBO damages the liver: the gut-liver axis

Here the story turns in a direction most people do not appreciate. The small intestine and the liver are joined anatomically and functionally. All blood leaving the gut — carrying nutrients, bacterial products and whatever else the intestinal lining permits through — travels via the portal vein directly to the liver. The liver is the first line of defence against anything crossing the gut barrier.

Normally the healthy gut epithelium is a highly selective barrier, admitting nutrients while keeping bacteria and their toxic byproducts out. SIBO disrupts that in several ways, and the consequences for the liver are significant.

1. Increased intestinal permeability ("leaky gut")

Bacteria in the small intestine produce enzymes and metabolites that damage the tight junctions between intestinal epithelial cells directly. Studies in animal models and humans both show SIBO associated with significantly increased intestinal permeability.²⁰ As tight junctions loosen, bacterial products — lipopolysaccharide (LPS) from gram-negative bacterial cell walls in particular — translocate across the gut wall into the portal circulation.

2. Lipopolysaccharide and liver inflammation

LPS is among the most potent known triggers of liver inflammation. Arriving at the liver via the portal vein, it binds Toll-like receptor 4 (TLR-4) on Kupffer cells, the liver's resident immune cells, setting off a cascade of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6.²¹ In acute doses this is a protective immune response. Chronically elevated, as in ongoing SIBO, it becomes persistent low-grade hepatic inflammation.

This pathway is not theoretical. A landmark study by Wigg and colleagues found significantly higher SIBO prevalence among patients with NASH than in healthy controls. Subsequent work has shown intestinal permeability increased in NAFLD/NASH, correlating with the severity of hepatic steatosis.²² In a real sense, gut bacteria appear to be fuelling liver inflammation.

3. Bile acid dysregulation

Normally, bile acids released by the liver into the small intestine to assist fat digestion are efficiently reabsorbed in the terminal ileum and recycled back to the liver — enterohepatic circulation. Bacteria in the small intestine deconjugate bile acids prematurely, converting them into forms that are poorly absorbed and cytotoxic to the intestinal lining.²³ This disrupts fat-soluble vitamin absorption, impairs the mucosal barrier, and alters the signalling functions of bile acids, which beyond digestion act as metabolic hormones regulating glucose, lipid and energy metabolism through receptors such as FXR and TGR5.²⁴

4. Short-chain fatty acid imbalance and hepatic steatosis

Short-chain fatty acids from colonic fermentation are generally beneficial. But excessive production of SCFAs — acetate especially — in the small intestine, from carbohydrate fermentation by SIBO bacteria, reaches the liver in large quantities and becomes substrate for de novo lipogenesis, liver fat production.²⁵ This is one mechanism by which SIBO may contribute directly to hepatic fat accumulation.

5. Ethanol production by gut bacteria

In a remarkable phenomenon known as auto-brewery syndrome or gut fermentation syndrome, certain small intestinal bacteria — notably Klebsiella pneumoniae — can produce significant quantities of ethanol from carbohydrate fermentation.²⁶ Even at sub-intoxicating levels, chronically elevated endogenous ethanol reaching the liver can promote oxidative stress and hepatocyte damage, mimicking aspects of alcoholic liver injury in people who drink little or no alcohol. A 2019 study in Cell Metabolism identified high-alcohol-producing strains of Klebsiella pneumoniae in approximately 60% of patients with non-alcoholic fatty liver disease, and showed that gavage of these strains induced fatty liver in mice.²⁷

Diagnosing SIBO: the current tools

The most widely used test is the lactulose or glucose hydrogen/methane breath test. You consume a sugar solution and breath hydrogen and methane are measured at intervals. Human cells do not produce these gases — only bacteria do — so elevated levels indicate fermentation in the small intestine.²⁸

The test has limitations: sensitivity and specificity vary, and lactulose tests in particular pose interpretation challenges. The gold standard, direct culture of small intestinal aspirate obtained by endoscopy, is invasive and rarely performed in practice. A positive breath test in the right clinical context is nonetheless generally considered adequate for diagnosis and treatment decisions.

An important note for women: cycle timing may matter. Some practitioners suggest testing in the follicular phase, early in the cycle, to avoid the confounding effects of progesterone-driven motility changes.

Treatment: addressing SIBO and protecting your liver

Antimicrobial treatment

Rifaximin, a non-absorbable antibiotic that stays in the gut, is the best-studied pharmaceutical treatment for hydrogen-dominant SIBO. Multiple RCTs demonstrate its efficacy both in normalising breath tests and in improving IBS-like symptoms.²⁹ For methane-dominant SIBO/IMO it is typically combined with neomycin for better efficacy.³⁰

Herbal antimicrobial protocols using combinations of berberine, allicin, oregano oil and neem have shown promising efficacy in small studies — one 2014 study found herbal therapy as effective as rifaximin for hydrogen SIBO.³¹ These may suit patients who prefer to avoid antibiotics or who have had recurrences.

Note: antibiotics alone frequently lead to recurrence if the underlying cause is not addressed. Recurrence rates within 9 months can reach 40–50%.³²

Addressing root causes (non-negotiable for lasting results)

• Support the MMC — space meals 4–5 hours apart to allow it to activate. Ginger has demonstrated prokinetic effects on gastric and small intestinal motility, and low-dose naltrexone has been used clinically to modulate motility in IBS, though evidence specific to SIBO recurrence is limited.³³

• Optimise thyroid function where hypothyroidism is present.

• Review and minimise PPI use with your doctor if long-term use is contributing.

• Treat underlying SIBO triggers — adhesions, structural issues, motility disorders.

• Stress management — given the HPA-gut axis relationship, this is genuine medicine.

Dietary support during and after treatment

• The low-FODMAP diet reduces the fermentable carbohydrates feeding SIBO bacteria and can significantly reduce symptoms during treatment, though it is not a cure.³⁴

• An elemental diet — a pre-digested liquid formula that starves the bacteria — has shown high success rates in normalising breath tests, and is used particularly in refractory or severe cases.³⁵

• After treatment, reintroduce diverse fibre gradually to support a healthy colonic microbiome. The goal is a thriving, diverse colon, not permanent bacterial restriction.

Protecting and supporting the liver

Given the liver involvement, specific strategies are warranted:

• Milk thistle (silymarin) — demonstrated hepatoprotective effects, reducing hepatic inflammation and supporting regeneration.³⁶

• Reduce gut bacterial load — treating SIBO effectively and durably is the most direct way to cut the LPS load reaching the liver.

• Avoid alcohol and unnecessary hepatotoxic medications during periods of suspected liver stress.

• Support bile flow — bile salts, choline and bitter herbs such as artichoke and dandelion support bile production and flow, aiding fat digestion and enterohepatic circulation.

When to seek further investigation

See a doctor promptly if you have:

• Unintentional weight loss

• Blood in stools

• Persistent vomiting

• New symptoms after the age of 50

• Elevated liver enzymes on blood work alongside gut symptoms

• Signs of malnutrition or significant nutrient deficiency

These warrant investigation to rule out more serious pathology before SIBO is assumed.

The bottom line

SIBO is not simply a bloating problem. It is a systemic condition with documented pathways to nutritional deficiency, hormonal disruption, skin disease, neurological symptoms and — critically — liver damage. Women face a unique convergence of risk factors: hormonal cycles, thyroid vulnerability, endometriosis, post-infectious susceptibility. Together these make them disproportionately affected.

Recognising that the gut and liver are in constant conversation, with everything crossing the small intestinal barrier travelling straight to the liver, reframes what taking gut health seriously actually means. It is not wellness jargon. It is anatomy.

References

Cited by the original article:

1. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443–1454. PMID: 17990113

2. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–1286. PMID: 19602448

3. Wald A, Van Thiel DH, Hoechstetter L, et al. Effect of pregnancy on gastrointestinal transit. Dig Dis Sci. 1982;27(11):1015–1018. PMID: 7140485

4. Lawson M, Kern F, Everson GT. Gastrointestinal transit time in human pregnancy. Gastroenterology. 1985;89(5):996–999. PMID: 4043680

5. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. PMID: 29340590

6. Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47(12):2639–2643. PMID: 12498278

7. Srivastava S, Bhatt SP, Mishra MN. Assessment of small intestinal bacterial overgrowth in subclinical and overt hypothyroidism. Indian J Gastroenterol. 2021;40(3):313–319. PMID: 34406634

8. Mathias JR, Franklin R, Quast DC, et al. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998;70(1):81–88. PMID: 9660426

9. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–3506. PMID: 11151884

10. Pimentel M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48(1):86–92. PMID: 12645795

11. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–2990. PMID: 20572300

12. Teo M, Chung S, Chitti L, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol. 2004;19(8):904–909. PMID: 15242494

13. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–764. PMID: 18456568

14. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926–938. PMID: 25689247

15. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158–1166. PMID: 560611

16. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–490. PMID: 23270866

17. Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth — prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–688. PMID: 23957651

18. Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10(5):e0126438. PMID: 25970536

19. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–599. PMID: 22314561

20. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887. PMID: 19358219

21. Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol. 2017;52(4):414–424. PMID: 28482048

22. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48(2):206–211. PMID: 11156641

23. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259. PMID: 16299351

24. Staels B, Fonseca VA. Bile acids and metabolic regulation. Diabetes Care. 2009;32(Suppl 2):S237–245. PMID: 19875558

25. Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586–591. PMID: 32214246

26. Painter K, Cordell BJ, Sticco KL. Auto-Brewery Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 29630222

27. Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675–688. PMID: 31543403

28. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. PMID: 28323273

29. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. PMID: 21208106

30. Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547–550. PMID: 20400905

31. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16–24. PMID: 24891990

32. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031–2035. PMID: 18802998

33. Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. J Clin Gastroenterol. 2009;43(4):e80–e86. PMID: 18813024

34. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75. PMID: 24076059

35. Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49(1):73–77. PMID: 14992438

36. Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301. PMID: 32006251